Abstract: A process for the production of urea wherein: production of pure urea (U) includes the concentration of an aqueous urea solution (23) by crystallization; a urea crystallization purge aqueous phase (32) comprising urea, water and biuret, which is purged from the urea crystallization process, is used in a high-biuret urea processing section (34) for additional production of urea with a high content of biuret.

Abstract: The disclosure provides for compounds and methods for modulating or inhibiting TEAD. Further provided herein are pharmaceutical compositions comprising the TEAD inhibitors and methods of treatment using the TEAD inhibitors or the pharmaceutical compositions.

Abstract: Disclosed herein are clusters compounds that include at least one substituted amine sulfate and at least one substituted amine bisulfate molecule. The substituted amine sulfate molecule and the substituted amine bisulfate molecule may each include an ammonium moiety with at least one alkyl substituent. Optionally, the alkyl substituent can include 1 to 20 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms. For example, the alkyl substituent can be a methyl, ethyl, propyl, butyl, or pentyl group. In some examples, the substituted amine sulfate molecule and the substituted amine bisulfate molecule each include an ammonium moiety with at least two alkyl substituents. Optionally, the two alkyl substituents are the same. Alternatively, however, the two alkyl substituents can be different.

Abstract: Disclosed by the present invention are an SIRT6 small-molecule allosteric activator and the application thereof and provided is an SIRT6 small-molecule allosteric activator that contains a derivative as shown in formula (1) or a pharmacologically acceptable salt thereof as the active ingredient. The SIRT6 small-molecule allosteric activator designed and synthesized in the present invention has high efficacy and low toxicity, may significantly activate SIRT6 activity during in vitro experiments, and has great importance in the development of pharmaceuticals for relevant diseases.

Abstract: Organic isocyanates are converted to ureas by heating in the presence of certain cobalt, magnesium, chromium and lanthanide series organometallic catalysts. The process requires no water or other reactants. The process is particularly useful for removing small quantities of monoisocyanates from a solvent stream recovered from a polyisocyanate manufacturing process. The urea compounds in some instances can be recycled back into the polyisocyanate manufacturing process and reacted with polyisocyanate compounds to form biurets.

Abstract: The present disclosure provides a process for making trifluoroacetyl iodide (TFAI) in a liquid phase reaction. Specifically, the present disclosure provides a liquid phase reaction of trifluoroacetyl chloride (TFAC) and hydrogen iodide (HI), with or without a catalyst, to form trifluoroacetyl iodide (TFAI). The reaction may be performed at ambient or elevated temperatures.

Abstract: An organic salt of the present disclosure contains terephthalic acid and at least one kind of primary alkylamine. An alkyl group constituting the primary alkylamine has 6 or more and 17 or less carbon atoms. The organic salt of the present disclosure can be used to detect a hydroxy radical contained in a gas, for example. The present disclosure provides: an organic salt that makes it possible to detect a hydroxy radical more easily as well as to detect a hydroxy radical generated in a living body; and a hydroxy-radical sensor adopting the organic salt.

Abstract: Monoisocyanate impurities are removed from a process stream obtained when solvent is separated from a polyisocyanate product. The monoisocyanates are reacted with amine compounds at specific molar ratios to produce ureas. The ureas can be discarded by burning, landfilling or otherwise. Alternatively the ureas can be recycled back into the polyisocyanate manufacturing process, where they are formed into biuret compounds that can remain with the polyisocyanate product.

Abstract: The present disclosure provides adamantyl compounds having one or more amine groups and one or more nitrate groups. The aminoadamantyl nitrate compounds can be used to treat disorders of the central nervous system, including neurodegenerative and non-neurodegenerative diseases.

Abstract: Disclosed are methods for preparing deuterated analogs of D-serine and compounds useful for preparing deuterated analogs of D-serine.

Abstract: A method for producing acetic acid includes an absorption step that suppresses corrosion inside a distillation column when a solution after that has absorbed a target component is subjected to distillation. The method for producing acetic acid also includes an absorption step of supplying, to an absorption column, at least a portion of offgas generated in an acetic acid production process, bringing the offgas into contact with an absorbent containing one or more liquids selected from a hydrocarbon, an ester of a carboxylic acid having 3 or more carbon atoms, an ester of a carboxylic acid and an alcohol having 2 or more carbon atoms, and an ether, to allow the absorbent to absorb an iodine compound in the offgas, and separating into a gas component having a lower iodine compound concentration than the offgas and a solution containing the absorbent and the iodine compound.

Abstract: The present application provides a method of preparing 4-[3-(3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one, or a pharmaceutically acceptable salt thereof, intermediates in the preparation thereof, methods of preparing the intermediates, and compositions and products comprising 4-[3-(3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fluorobenzyl]phthalazin-1(2H)-one made from the methods that result in high purity and yield.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Oseltamivir is used as active agent to treat a hearing impairment and to prevent a hearing impairment, and a method of treating and/or preventing hearing impairments or disorders using Oseltamivir are disclosed. Oseltamivir exhibits excellent protection against noise-induced hearing loss and against cisplatin-induced hearing loss.

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

Abstract: Provided is a compound of Formula (I): wherein the variable groups are defined herein.

Abstract: The present disclosure relates to a novel crystalline form of Tolebrutinib (hereinafter referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline form, and uses of the crystalline form for preparing BTK inhibitor drugs and drugs for treating multiple sclerosis.

Abstract: Provided herein, in certain embodiments, are compounds of Formula I. or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).

Abstract: A nutritional supplement is described that is useful in combination with radiotherapy to reduce the growth of tumor stem cells. The nutritional supplement includes selenium and fish oil, and has been also found to be effective in reducing negative side effects of concurrent radiotherapy, including inflammation, weight loss, muscle wasting, neutropenia, and loss of cells from the lining of the gut.

Abstract: The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.